The American journal of tropical medicine and hygiene · 2020
Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ngabonziza Jean Claude Semuto, Van Deun Armand, Migambi Patrick, Niyigena Esdras Belamo, Dusabe Théogène, Habimana Yves Mucyo, Ushizimpumu Bertin, Mulders Wim, Decroo Tom, Affolabi Dissou, Supply Philip, de Jong Bouke C, Rigouts Leen
Аннотация
We report a case of acquired fluoroquinolone (FQ) resistance under short-course multidrug-resistant tuberculosis (MDR-TB) treatment. The patient was managed at Kabutare hospital, one of the two specialized MDR-TB clinics in Rwanda. A low dose of moxifloxacin was used in the first three critical months. Acquired resistance was identified at the ninth month of treatment, 3 months after stopping kanamycin in a strain initially susceptible only to FQs, kanamycin, and clofazimine. Fluoroquinolone resistance was detected in the same month by deep sequencing as routinely used second-line line probe assay and phenotypic drug susceptibility testing. High-dose FQ, preferably gatifloxacin, should be used to maximize effectiveness.
Предметные рубрики MeSH
Antitubercular AgentsClofazimineDrug Resistance, Multiple, BacterialFemaleFluoroquinolonesGatifloxacinGenes, BacterialHigh-Throughput Nucleotide SequencingHumansKanamycinMicrobial Sensitivity TestsMiddle AgedMoxifloxacinMycobacterium tuberculosisRwandaSequence Analysis, DNATuberculosis, Multidrug-Resistant